

EAGLE PHARMACEUTICALS, INC.
 Form 3
 February 11, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * ProQuest Associates IV LLC (Last) (First) (Middle) 2430 VANDERBILT BEACH ROAD, 108-190 (Street) NAPLES, FL 34109 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/11/2014	3. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
---	--	---	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, \$0.001 par value	39,001	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Common Stock, \$0.001 par value	9,360	I	By ProQuest Management LLC <u>(2)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	1,927,986 <u>(5)</u>	\$ 0	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Series B Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	1,028,613 <u>(5)</u>	\$ 0	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Series B-1 Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	850,520 <u>(5)</u>	\$ 0	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Series C Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	569,538 <u>(5)</u>	\$ 0	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Series C Warrants	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	98,368 <u>(5)</u>	\$ 11.67	I	By ProQuest Investments IV, L.P. <u>(1)</u>
Series B-1 Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	62,575 <u>(5)</u>	\$ 0	I	By ProQuest Management LLC Plans <u>(7)</u>
Series C Convertible Preferred Stock	Â <u>(3)</u>	Â <u>(4)</u>	Common Stock	9,359 <u>(5)</u>	\$ 0	I	By ProQuest Management LLC Plans <u>(7)</u>
Series C Warrants	Â <u>(6)</u>	Â <u>(6)</u>	Common Stock	1,614 <u>(5)</u>	\$ 11.67	I	By ProQuest Management LLC Plans <u>(7)</u>
Stock Option (right to buy)	Â <u>(8)</u>	03/06/2018	Common Stock	2,340	\$ 0.14	I	By ProQuest Management LLC <u>(2)</u>
Stock Option (right to buy)	Â <u>(9)</u>	06/09/2019	Common Stock	2,340	\$ 0.63	I	By ProQuest Management LLC <u>(2)</u>
Stock Option (right to buy)	Â <u>(10)</u>	03/06/2020	Common Stock	2,340	\$ 1.37	I	By ProQuest Management LLC <u>(2)</u>
Stock Option (right to buy)	Â <u>(11)</u>	07/12/2021	Common Stock	2,340	\$ 1.37	I	By ProQuest Management LLC <u>(2)</u>
	Â <u>(12)</u>	07/12/2022		2,340	\$ 1.37	I	

Stock Option (right to buy)

Common Stock

By ProQuest Management LLC
(2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ProQuest Associates IV LLC 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109	Â	Â X	Â	Â
ProQuest Investments IV, L.P. 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109	Â	Â X	Â	Â
ProQuest Management LLC 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109	Â	Â X	Â	Â

Signatures

ProQuest Associates IV, LLC /s/ Pasquale DeAngelis, Managing Member ProQuest Investments IV, L.P. its General Partner /s/ Pasquale DeAngelis, Managing Member ProQuest Management LLC /s/ Pasquale DeAngelis, Administrative Partner	02/11/2014
__Signature of Reporting Person	Date
Pasquale DeAngelis, Managing Member	02/11/2014
__Signature of Reporting Person	Date
Pasquale DeAngelis, Administrative Partner	02/11/2014
__Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares are owned by ProQuest Investments IV, L.P. ("Investments IV"), of which ProQuest Associates IV LLC ("Associates IV") is the general partner. Jay Moorin and Alain Schreiber are managing members of Associates IV. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.
- (2) The shares are owned by ProQuest Management LLC ("ProQuest Management"). Jay Moorin and Alain Schreiber are managing members of ProQuest Management. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.
- (3) Immediately convertible. The Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series C Convertible Preferred stock automatically convert into shares of Issuer's common stock immediately prior to the completion of Issuer's initial public offering.
- (4) The expiration date is not relevant to the conversion of these securities.
- (5) Reflects a 1-for-6.41 reverse stock split, pursuant to which each share of preferred stock became convertible into 1/6.41 of a share of common stock.
- (6) In accordance with their terms, the Series C Warrants (the "Warrants") will be net exercised immediately prior to closing of the Issuer's initial public offering into shares of common stock.

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 3

- The shares are held in a ProQuest Management LLC Defined Benefit Pension Plan ("DBPP") FBO Jay Moorin and a ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Jay Moorin and Alain Schreiber
- (7) are trustees of the ProQuest Management LLC DBPP FBO Jay Moorin and the ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.
- (8) 25% of the shares subject to the option vest in equal annual installments commencing on March 6, 2009.
- (9) 25% of the shares subject to the option vest in equal annual installments commencing on June 9, 2010.
- (10) 25% of the shares subject to the option vest in equal annual installments commencing on March 6, 2011.
- (11) 25% of the shares subject to the option vest in equal annual installments commencing on July 12, 2012.
- (12) 25% of the shares subject to the option vest in equal annual installments commencing on June 12, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.